Smith Geoffrey Wade
Known title: DirectorCIK: 0001418239
Associated companies
Transaction History
| OBIO | ▲ Buy | Grant | 16,667 | $0 | 7/20/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 758 | — | 4/12/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 43,761 | — | 4/12/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 228,073 | — | 4/12/2023 | View on chart |
| OBIO | ▲ Buy | Option Exercise | 55,783 | — | 4/12/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 3,488 | — | 1/26/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 201,319 | — | 1/26/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 1,049,224 | — | 1/26/2023 | View on chart |
| OBIO | ▲ Buy | Grant | 256,623 | — | 1/26/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
OBIO Shares Rise 5.2% Amid Positive Momentum
Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.
OBIO Shares Rise 5.2% Amid Positive Momentum. Orchestra BioMed Holdings (OBIO) shares recently increased by 5.2%, a move that some observers see as a sign of strengthening momentum. The stock currently trades within its 52-week range of $2.20 to $6.48. Analysts maintain an average price target of $12.14, suggesting a significant gap between the current market price and professional estimates.